Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States

INTRODUCTION: Imatinib is standard therapy for patients with chronic myeloid leukemia (CML). In February 2016, a generic formulation entered the US market. Physicians and patients are frequently concerned about whether switching from original to generic drugs may affect the efficacy and/or safety. M...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Med
Main Authors: Abou Dalle, Iman, Kantarjian, Hagop, Burger, Jan, Estrov, Zeev, Ohanian, Maro, Verstovsek, Srdan, Ravandi, Farhad, Borthakur, Gautam, Garcia‐Manero, Guillermo, Jabbour, Elias, Cortes, Jorge
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2019
Assuntos:
Clinical Cancer Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6825993/
https://ncbi.nlm.nih.gov/pubmed/31502383
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2545
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares